5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists), 5-HT7 receptor antagonists(Serotonin 7 (5-HT7) receptor antagonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication

Dementia due to Parkinson's diseaseProgressive Supranuclear Palsy Atypical

Originator Organization

IRLAB Therapeutics AB

Active Organization

IRLAB Therapeutics AB

The University of Manchester

University of Gothenburg

+ [1]

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC11H13F2NO

InChIKeyLJNFYMMXCXGFCP-LLVKDONJSA-N

CAS Registry1227638-29-0

Clinical Trials associated with Pirepemat

NCT05258071

/ CompletedPhase 2

A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.

Start Date15 Jun 2022

Sponsor / Collaborator

IRLAB Therapeutics AB

EUCTR2017-001673-17-FI

/ CompletedPhase 2

A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia

Start Date03 Oct 2017

Sponsor / Collaborator

IRLAB Therapeutics AB

100 Clinical Results associated with Pirepemat

100 Translational Medicine associated with Pirepemat

100 Patents (Medical) associated with Pirepemat

Literatures (Medical) associated with Pirepemat

01 Dec 2021·Clinical pharmacology in drug development

First‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers

Article

Author: Waters, Nicholas ; Sjöberg, Folke ; Tedroff, Joakim ; Sonesson, Clas ; Huss, Fredrik ; Waters, Susanna ; Rein‐Hedin, Erik

Abstract:

Pirepemat (IRL752) is a cortical enhancer being developed for the prevention of falls in patients with Parkinson disease. This first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1 study evaluated safety, tolerability, and pharmacokinetics (PK) of pirepemat administered as oral single ascending doses (10, 35, 75, 175, 350 mg) and multiple ascending doses (100 and 250 mg 3 times daily) for 7 days to healthy male volunteers. Twenty and 24 subjects were randomly assigned in the single ascending dose and multiple ascending doses parts of the study, respectively. Pirepemat was generally well tolerated, although an increased frequency of adverse events of mild intensity within nervous system disorders (headache and dizziness) was seen after administration of 350 mg as a single dose and after multiple doses of 100 and 250 mg. PK of pirepemat showed a linear relationship over the dose range studied and exhibited dose proportionality after multiple‐dose administration. Accumulation after 7 days of multiple dosing was minor. Absorption was rapid, with a median time to maximum concentration of 2.0 hours on day 1 and day 7 (100 and 250 mg) and a mean terminal half‐life between 3.7 and 5.2 hours. Food intake had no (obvious) impact on PK. The results support 3‐times‐daily dosing and further clinical development.

01 Sep 2020·The Journal of pharmacology and experimental therapeuticsQ3 · MEDICINE

(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent

Q3 · MEDICINE

Article

Author: Svensson, P ; Ljung, E ; Waters, N ; Sonesson, C ; Neill, J C ; Hjorth, S ; Fagerberg, A ; Idris, N F ; Grayson, B ; McLean, S L ; Tedroff, J ; Edling, M ; Gunnergren, J ; Svanberg, B ; Waters, S

Here we describe for the first time the distinctive pharmacological profile for (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752), a new phenyl-pyrrolidine derivative with regioselective central nervous system transmission-enhancing properties. IRL752 (3.7-150 µmol/kg, s.c.) was characterized through extensive in vivo studies using behavioral, tissue neurochemical, and gene expression as well as microdialysis methods. Behaviorally, the compound normalized tetrabenazine-induced hypoactivity, whereas it was unable to stimulate basal locomotion in normal animals or either accentuate or reverse hyperactivity induced by amphetamine or MK-801. IRL752 induced but minor changes in monoaminergic tissue neurochemistry across noradrenaline (NA)- and dopamine (DA)-dominated brain regions. The expression of neuronal activity-, plasticity-, and cognition-related immediate early genes (IEGs), however, increased by 1.5-fold to 2-fold. Furthermore, IRL752 dose-dependently enhanced cortical catecholamine dialysate output to 600%-750% above baseline, whereas striatal DA remained unaltered, and NA rose to ∼250%; cortical and hippocampal dialysate acetylcholine (ACh) increased to ∼250% and 190% above corresponding baseline, respectively. In line with this cortically preferential transmission-promoting action, the drug was also procognitive in the novel object recognition and reversal learning tests. In vitro neurotarget affinity and functional data coupled to drug exposure support the hypothesis that 5-hydroxytryptamine 7 receptor and α2(C)-adrenoceptor antagonism are key contributors to the in vivo efficacy and original profile of IRL752. The cortical-preferring facilitatory impact on catecholamine (and ACh) neurotransmission, along with effects on IEG expression and cognition-enhancing features, are in line with the potential clinical usefulness of IRL752 in conditions wherein these aspects may be dysregulated, such as in axial motor and cognitive deficits in Parkinson disease. SIGNIFICANCE STATEMENT: This report describes the distinctive preclinical profile of (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752). Its in vivo neurochemical, behavioral, microdialysis, and gene expression properties are consistent with a cortically regioselective facilitatory impact on catecholaminergic and cholinergic neurotransmission accompanied by cognitive impairment-reversing features. The pharmacological characteristics of IRL752 are in line with the clinical usefulness of IRL752 in conditions wherein these aspects may be dysregulated, such as in axial motor and cognitive deficits in Parkinson disease.

01 Jun 2020·Movement disorders : official journal of the Movement Disorder SocietyQ1 · MEDICINE

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

Q1 · MEDICINE

Article

Author: Sotirios Grigoriou ; Juha Rinne ; Clas Sonesson ; Panagiota Tsitsi ; Fredrik Hansson ; Anders Johansson ; Nil Dizdar ; Filip Bergquist ; Joakim Tedroff ; Per Odin ; Per Svenningsson ; Klas Wictorin ; for the IRL752 Collaborators ; Dag Nyholm

Abstract:

Background:

IRL752 is a novel small‐molecule compound that acts to regioselectively enhance norepinephrine, dopamine, and acetylcholine neurotransmission in the cerebral cortex.

Objective:

The primary objective of the trial was to investigate the safety and tolerability of IRL752 in patients with Parkinson's disease and dementia.

Methods:

Patients with Parkinson's disease and dementia were randomized to IRL752 or placebo treatment (3:1 ratio) for 28 days. The study drug was given as an adjunct treatment to the patients’ regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days after which the dose was kept stable for an additional 14 days.

Results:

A total of 32 patients were randomized to treatment, and 29 patients completed the 4‐week treatment. Adverse events were generally mild and transient and were mostly reported during the dose titration phase. There were 2 serious adverse events, and none of them were related to the experimental treatment. The average dose achieved in the stable dose phase was 600 mg daily, yielding a 2‐hour postdose plasma concentration of about 4 μM on day 28. Exploratory assessment of secondary outcomes indicated efficacy for symptoms and signs known to be poorly responsive to levodopa.

Conclusions:

179

News (Medical) associated with Pirepemat

20 Oct 2026

·www.biospace.com

Nomination Committee Appointed for IRLAB’s Annual General Meeting 2027

GOTHENBURG, SE / ACCESS Newswire / October 20, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces that the nomination committee ahead of the annual general meeting (AGM) 2027 has been appointed. According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual general meeting on May 22, 2024, the nomination committee shall, besides the Chair of the Board, consist of representatives of the three largest shareholders, or groups of shareholders, as of the last banking day in August 2026. The three largest shareholders or groups of shareholders have now appointed their representatives, thus the nomination committee ahead of the AGM 2027 has the following members: Daniel Johnsson , entrepreneur, business developer and investor. Appointed by a group of shareholders that consists of the company's founders representing about 11 per cent of shares and votes (Chairman) Joakim Tedroff , Chief Medical Officer (CMO) at IRLAB and one of IRLAB's founders. Appointed by a group of shareholders that consists of the company's founders representing about 8 per cent of shares and votes Patrik Mossberg , CEO and chairman of Marinvest representing about 3 per cent of shares and votes Janne Backman , Chair of the Board of IRLAB Therapeutics AB. Daniel Johnsson has been appointed Chairman of the nomination committee. The members of the nomination committee have been appointed by owners in IRLAB Therapeutics AB who represent a total of about 22 per cent of the total number of shares and votes in IRLAB Therapeutics AB as of the last banking day in August 2026. Information about the nomination committee's work and the instruction to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee's proposal will be presented in the summon to the annual general meeting 2027 and on the company's web page, . The annual general meeting is planned to be held on June 3, 2027. Shareholders who wish to submit proposals to the nomination committee shall do this in writing, no later than January 31, 2027, via e-mail ir@irlab.se. For more information Kristina Torfgård, CEO Phone: +46 730 60 70 99 E-mail: kristina.torfgard@irlab.se For more information Gustaf Albèrt, CFO Phone: +46 709 168 302 E-mail: gustaf.albert@irlab.se About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments Nomination committee appointed for IRLAB’s annual general meeting 2027 SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

Phase 2Phase 1Executive Change

24 Sep 2026

·www.biospace.com

IRLAB Appoints Janne Backman as New Chairman of the Board

GOTHENBURG, SWEDEN / ACCESS Newswire / September 24, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, announces that Jan-Fredrik ("Janne") Backman today assumes the role of Chairman of the Board. He was elected Vice Chairman at the 2026 Annual General Meeting and now succeeds Carola Lemne, who announced back in the spring that she intended to step down from the position in September. Janne Backman has more than 20 years of experience in the life science industry. He has held positions including Senior Global Strategy and Marketing Director, Global Strategy and Marketing Director, and Global Program Director within R&D at The Medicines Company, where he led international commercialization strategies, EU product launches, and global development programs. In addition, he has held commercial roles at Merck Serono and AstraZeneca. Since 2016, he has served as CEO of J.F.B Consulting AB and J.F.B Invest. "It has been a privilege to lead IRLAB's Board of Directors during a period in which the company has built one of the most innovative and broadest pipelines in the Parkinson's disease field. After eight years of service on the Board, this feels like the right time to hand over the chairmanship. I am confident that Janne Backman, along with the rest of the Board, will contribute to maximizing the company's value creation for both patients worldwide and our shareholders," says Carola Lemne, outgoing Chairman of the Board of IRLAB Therapeutics. "On behalf of the entire Board, I would like to thank Carola Lemne for her contributions as Chairman of the Board. I look forward to leading the continued efforts to advance IRLAB's drug development programs and strengthen the company's ability to establish partnerships with international pharmaceutical companies," says Janne Backman, incoming Chairman of the Board of IRLAB Therapeutics. About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . For more information Jan-Fredrik Backman, Chairman Tel: +46 702 35 65 00 E-post: janne.backman@irlab.se Kristina Torfgård, CEO Tel: +46 730 60 70 99 E-post: kristina.torfgard@irlab.se Attachments IRLAB Appoints Janne Backman as New Chairman of the Board SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

Phase 2Executive ChangePhase 1

03 Sep 2026

·www.biospace.com

IRLAB’s CEO Intends to Step Down During the First Quarter of 2027

GOTHENBURG, SE / ACCESS Newswire / September 3, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announces today that Kristina Torfgård has informed the Board of Directors that she wishes to step down from her position as CEO. She will remain in the CEO role until the first quarter of 2027, creating good conditions for a smooth transition to her successor. The Board of Directors will immediately initiate the work to ensure a well-structured leadership transition. "On behalf of the Board of Directors, I would like already now to extend a warm thank you to Kristina Torfgård for her contributions as CEO. We appreciate that she has notified the Board of her intention with such good advance notice and are convinced that she will continue her solid and committed work so that IRLAB can bring the ongoing partner discussions all the way to completion. At the same time, progress continues in the ongoing clinical study of the drug candidate linepemat, and the company's financial runway extends beyond the planned readout of results in mid-2027. We are now immediately initiating the process of finding a suitable successor for the CEO position," says Carola Lemne, Chair of the Board of IRLAB Therapeutics. "It is with mixed feelings that I have informed the Board that I wish to leave IRLAB, a company that I am proud to have been part of. With a successful capital raise behind us and intensive ongoing activities to secure the next revenue-generating collaboration agreement, I now look forward to continuing to work to deliver on our stated goals until I take the next step in my professional life at the beginning of next year," says Kristina Torfgård, CEO of IRLAB Therapeutics. For more information: ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Carola Lemne, Chair of the Board Phone: +46 722 25 28 20 E-mail: carola.lemne@irlab.se This information is information that IRLAB Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-09-03 10:55 CEST. About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Attachments IRLAB’s CEO intends to step down during the first quarter of 2027 SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

Phase 2Phase 1Executive Change

100 Deals associated with Pirepemat

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 2	France	IRLAB Therapeutics AB	15 Jun 2022
Parkinson Disease	Phase 2	Germany	IRLAB Therapeutics AB	15 Jun 2022
Parkinson Disease	Phase 2	Netherlands	IRLAB Therapeutics AB	15 Jun 2022
Parkinson Disease	Phase 2	Poland	IRLAB Therapeutics AB	15 Jun 2022
Parkinson Disease	Phase 2	Spain	IRLAB Therapeutics AB	15 Jun 2022
Parkinson Disease	Phase 2	Sweden	IRLAB Therapeutics AB	15 Jun 2022
Dementia due to Parkinson's disease	Phase 2	Finland	IRLAB Therapeutics AB	03 Oct 2017
Progressive Supranuclear Palsy Atypical	Phase 2	Finland	IRLAB Therapeutics AB	03 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05258071 (CTgov)	Phase 2	Parkinson Disease	104	Placebo	qmzbblxrar(huaiydpzfk) = fpaupedlgd dqaggadgva (jvoovxcpyu, 90.22) View more	-	09 Jul 2026
MDS2019	Phase 2	Progressive Supranuclear Palsy Atypical	-	IRL752	cfwevyfiqn(bvtnigdohl) = IRL752 treatment may improve apathy ufgtnlnyes (tschuljapp ) View more	Positive	22 Sep 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis